Abstract:Novel bifunctional thienopyridine derivatives linked by an ester bond demonstrate simultaneous targeting of FXa and P2Y12 receptors. These compounds act as mutual prodrugs, combining anticoagulant and antiplatelet activity in a single molecule. This approach offers potential advantages in the treatment of cardiovascular disease through simplified administration and synergistic therapeutic effects. Thienopyridine derivatives are specifically designed for utilization in antithrombotic therapy to help combat cardiovascular disorders linked to thrombosis. This study introduces new thienopyridine derivatives with superior therapeutic efficacy through synergies by dual functional compounds, developed as antithrombotic agents. Through computational design, we discovered 32 compounds out of a library of 100 compounds that exhibit efficacy. The compounds are synthesized by multiple steps and subsequently purified using chromatographic procedures to achieve a purity level of >99%. Using the ADP‐induced platelet aggregation assay, we have found 4 active test compounds (ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03) out of a total of 32 compounds. On the other hand, ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03 have demonstrated the highest percentage activity on factor Xa (FXa) inhibition. The ACG‐A‐04 chemical exhibited the highest hydrophilicity, specifically in terms of its aqueous solubility. It had a solubility of 0.44 mg/mL in pH 5.8, 0.29 mg/L in pH 6.2, and 0.145 mg/L in pH 7.4 buffers. In comparison, the standards APX‐01 (apixaban) and PRG‐01(prasugrel) had lower hydrophilicity. Based on cytotoxicity investigations, it was determined that the test substances do not exhibit harmful effects. The results indicated that the test chemicals can undergo hydrolysis in blood plasma rather than in other organs. Among the four test drugs, ACG‐1073‐19 exhibited an unbound fraction of 44.1%, which is twice as high as the standards (apixaban). ACG‐1073‐37 demonstrates superior plasma protein binding (33.2%) compared to all other test compounds. The compounds resulted in a higher expression of CD61, CD42b, and CD62P in platelets compared to the control. The ACG‐1073‐37 molecule had a Caco‐2 permeability of 51%, which is extremely close to the Caco‐2 permeability of the control medicines (55% for APX‐01 and 62% for PRG‐01). Through the assessment of microsomal stability, it was determined that ACG‐1073‐37 and ACG‐A‐04 exhibited metabolic stability for 42.4 and 34.14 min, respectively.

Design, Synthesis, Anticoagulant Activity Evaluation and Molecular Docking Studies of A Class of N-Ethyl Dabigatran Derivatives

Preclinical Study on a Novel Fluoroderivative of Dabigatran Etexilate in Animal Models

Synthesis of CC, CN coupled novel substituted dibutyl benzothiazepinone derivatives and evaluation of their thrombin inhibitory activity.

Cleavable Novel Thienopyridine Derivatives as Potent Antithrombotic Agents

Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment

Novel Thiourea and Oxime Ether Isosteviol-Based Anticoagulants: MD Simulation and ADMET Prediction

Molecular assembly for high-performance bivalent nucleic acid inhibitor

Comparative Molecular Field Analysis Of Non-Peptidic Inhibitors Of Thrombin

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

A Novel Hirudin Derivative Inhibiting Thrombin Without Bleeding for Subcutaneous Injection.

Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors

Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments

A Network-Based Multi-Target Computational Estimation Scheme for Anticoagulant Activities of Compounds.

Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment

In silico design, docking simulation, and ANN-QSAR model for predicting the anticoagulant activity of thiourea isosteviol compounds as FXa inhibitors

Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

Synthesis, characterization and thrombolytic activity evaluation of novel pyrazolo[3,4- b ]pyridine-4-carbohydrazide derivatives

Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy

A New Class of Anti-Thrombosis Hexahydropyrazino-[1′,2′:1,6]Pyrido-[3,4-b]-indole-1,4-dions: Design, Synthesis, Log K Determination, and QSAR Analysis

Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa